Diclofenac Does Not Reduce the Risk of Post-endoscopic Retrograde Cholangiopancreatography Pancreatitis in Low-Risk Units

Show simple item record

dc.contributor.author Rainio, Mia
dc.contributor.author Lindström, Outi
dc.contributor.author Udd, Marianne
dc.contributor.author Louhimo, Johanna
dc.contributor.author Kylänpää, Leena
dc.date.accessioned 2018-08-18T21:12:52Z
dc.date.available 2021-12-17T22:01:35Z
dc.date.issued 2017-08
dc.identifier.citation Rainio , M , Lindström , O , Udd , M , Louhimo , J & Kylänpää , L 2017 , ' Diclofenac Does Not Reduce the Risk of Post-endoscopic Retrograde Cholangiopancreatography Pancreatitis in Low-Risk Units ' , Journal of Gastrointestinal Surgery , vol. 21 , no. 8 , pp. 1270-1277 . https://doi.org/10.1007/s11605-017-3412-3
dc.identifier.other PURE: 88441527
dc.identifier.other PURE UUID: 69418429-bf5c-452d-8623-3188b8832713
dc.identifier.other WOS: 000406026400010
dc.identifier.other Scopus: 85016931308
dc.identifier.other ORCID: /0000-0002-6208-978X/work/41174760
dc.identifier.uri http://hdl.handle.net/10138/238725
dc.description.abstract Background Nonsteroidal anti-inflammatory drugs have an inhibitory role in pathogenesis of pancreatitis. Guidelines from the European Society of Gastrointestinal Endoscopy recommend routine rectal administration of 100 mg of diclofenac or indomethacin immediately before or after ERCP for all patients without contraindications. Aims Our aim was to evaluate the effect of diclofenac in preventing post-ERCP pancreatitis (PEP) in a high-volume, low-PEP-risk ERCP unit. Methods The rate and severity of PEP were compared in groups of 1000 historical controls prior to the routine use of diclofenac and in 1000 patients receiving 100 mg diclofenac before ERCP. Results PEP occurred in 56 (2.8%) of the 2000 patients, and the rate of the pancreatitis was 2.8% in control group and 2.8% in diclofenac group (p = 1.000). The PEP rate among the native papilla patients was 3.9% in control group and 3.6% in diclofenac group (p = 0.803). In subgroup analysis of patients with a high risk of PEP, diclofenac neither prevented PEP nor made its course milder. Conclusions In an unselected patient population in a center with a low incidence of PEP, diclofenac seems to have no beneficial effect. en
dc.format.extent 8
dc.language.iso eng
dc.relation.ispartof Journal of Gastrointestinal Surgery
dc.rights.uri info:eu-repo/semantics/openAccess
dc.subject Acute pancreatitis
dc.subject Diclofenac
dc.subject ERCP
dc.subject ESGE recommendation
dc.subject Post-ERCP pancreatitis
dc.subject NONSTEROIDAL ANTIINFLAMMATORY DRUGS
dc.subject ERCP PANCREATITIS
dc.subject RECTAL INDOMETHACIN
dc.subject RANDOMIZED-TRIAL
dc.subject METAANALYSIS
dc.subject PREVENTION
dc.subject COMPLICATIONS
dc.subject NSAIDS
dc.subject SPHINCTEROTOMY
dc.subject MULTICENTER
dc.subject 3126 Surgery, anesthesiology, intensive care, radiology
dc.title Diclofenac Does Not Reduce the Risk of Post-endoscopic Retrograde Cholangiopancreatography Pancreatitis in Low-Risk Units en
dc.type Article
dc.contributor.organization II kirurgian klinikka
dc.contributor.organization Clinicum
dc.contributor.organization HUS Abdominal Center
dc.contributor.organization University of Helsinki
dc.contributor.organization Department of Surgery
dc.description.reviewstatus Peer reviewed
dc.relation.doi https://doi.org/10.1007/s11605-017-3412-3
dc.relation.issn 1091-255X
dc.rights.accesslevel openAccess
dc.type.version publishedVersion
dc.identifier.url http://rdcu.be/u6pm

Files in this item

Total number of downloads: Loading...

Files Size Format View
10.1007_s11605_017_3412_3.pdf 453.5Kb PDF View/Open

This item appears in the following Collection(s)

Show simple item record